Ultra Low Frequency Spinal Cord Stimulation for Chronic Low Back Pain

Chronic Pain Clinical Trial

Official title:

A Prospective, Open-Label, Multi-Center Trial to Evaluate the Safety and Effectiveness of Ultra Low Frequency Spinal Cord Stimulation in Patients With Chronic Low Back Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05837234
• Other study ID #: PMH-003
• Status: Recruiting
• Phase: N/A
• Start date: May 9, 2023
• Est. completion date: June 2025

Study information

• Verified date: December 2023
• Source: Presidio Medical, Inc
• Contact: Valerie Cimmarusti
• Phone: +1 (626) 353-8667
• Email: vcimmarusti[@]presidiomedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Presidio Medical Ultra Low Frequency (ULF™) Spinal Cord Stimulation (SCS) System is intended to provide pain relief to participants who have been clinically diagnosed with chronic low back pain with or without leg pain.

Description:

This is a prospective, open-label, multi-center clinical trial in which participants with chronic low back pain (CLBP) with/without leg pain will be invited to enroll and undergo treatment with the ULF SCS system. The purpose of this study is to evaluate the safety and effectiveness of ULF SCS over a 1-year period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 55
• Est. completion date: June 2025
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosed with chronic low back pain with/without leg pain (VAS =60mm for back pain for the past week), which has been refractory to conservative therapy for a minimum of 3 months.

2. Be on no or stable pain medications, as determined by the investigator, for at least 28 days prior to the screening visit.

3. Is currently considered medically stable as judged by investigator.

4. Able to operate the SCS device (e.g., using remote control) and charge the device appropriately.

5. Determined to be a good surgical candidate by the investigator.

6. Willing to sign the Human Research Ethics Committee (HREC) approved informed consent and deemed capable of complying with the requirements of the study protocol.

7. Willing to stay on stable medications until implantable pulse generator (IPG) activation (i.e., from IPG implant to IPG activation, except for usual postoperative medications required following IPG insertion).

8. Able to comply with study requirements and attend all scheduled visits.

9. Eighteen (18) years of age or older.

10. Literate, able to speak English and able to complete questionnaires independently.

Exclusion Criteria:

1. Diagnosis of active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance, intervention and/or ability to evaluate treatment outcome as assessed by a clinical psychologist or psychiatrist in a psychological assessment performed at Baseline.

2. Chronic pain in any area other than back or legs, such that it precludes subject's ability to assess their pain for the primary indication of chronic low back pain as determined by Investigator.

3. Previous experience with implantable neuromodulation devices (e.g., spinal cord stimulation, peripheral nerve stimulation, dorsal root ganglion stimulation).

4. Opioid usage with average total daily morphine equivalent dose (MED) of >60 mg.

5. A known need for an MRI or surgery within a 2-week period of the screening visit through the end of the study.

6. Female candidates of childbearing potential that are pregnant (confirmed by positive urine/blood pregnancy test) or plan to get pregnant during the duration of the study.

7. Subject is participating in another interventional clinical trial.

Related Conditions & MeSH terms

• Back Pain
• Chronic Low-back Pain
• Chronic Pain
• Low Back Pain

Intervention

Device:
• ULF SCS
Ultra low frequency spinal cord stimulation

Locations

Country	Name	City	State
Australia	Metro Pain Research Institute	Clayton	Victoria
Australia	Genesis Research Services Pty Ltd	Newcastle	New South Wales
Australia	CerCare Pty Ltd	Wayville	South Australia

Sponsors (1)

Lead Sponsor	Collaborator
Presidio Medical, Inc

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Back pain responder rate at 3 months as assessed using a visual analog scale (VAS)	A responder is defined as a participant that achieved at least 50% reduction in back pain at the follow-up compared to baseline. Responder rate is defined as the percentage of participants that were responders.	3 months
Secondary	Change in back pain VAS at 3 months	The mean percentage change in VAS back pain intensity from baseline.	3 months
Secondary	Change in back pain VAS at 6 months	The mean percentage change in VAS back pain intensity from baseline.	6 months
Secondary	Change in back pain VAS at 12 months	The mean percentage change in VAS back pain intensity from baseline.	12 months
Secondary	Change in leg pain VAS at 3 months	The mean percentage change in VAS leg pain intensity from baseline. Calculated only for participants who scored at least 40 out of 100mm for leg pain at baseline.	3 months
Secondary	Change in leg pain VAS at 6 months	The mean percentage change in VAS leg pain intensity from baseline. Calculated only for participants who scored at least 40 out of 100mm for leg pain at baseline.	6 months
Secondary	Change in leg pain VAS at 12 months	The mean percentage change in VAS leg pain intensity from baseline. Calculated only for participants who scored at least 40 out of 100mm for leg pain at baseline.	12 months
Secondary	Proportion of participants with a minimal clinically important difference (MCID) as measured by Oswestry Disability Index (ODI) at 3 months	The MCID is defined as at least a 10-point improvement on ODI.	3 months
Secondary	Proportion of participants with a MCID as measured by ODI at 6 months	The MCID is defined as at least a 10-point improvement on ODI.	6 months
Secondary	Proportion of participants with a MCID as measured by ODI at 12 months	The MCID is defined as at least a 10-point improvement on ODI.	12 months
Secondary	Change in EuroQol-5 Dimension (EQ-5D) quality of life index at 3 months	The mean change in EQ-5D index from baseline.	3 months
Secondary	Change in EQ-5D quality of life index at 6 months	The mean change in EQ-5D index from baseline.	6 months
Secondary	Change in EQ-5D quality of life index at 12 months	The mean change in EQ-5D index from baseline.	12 months
Secondary	Proportion of participants with remission of low back pain as assessed by VAS at 6 months	Remission is defined as VAS score of 30mm or less for 6 consecutive months.	6 months
Secondary	Proportion of participants with remission of low back pain as assessed by VAS at 9 months	Remission is defined as VAS score of 30mm or less for 6 consecutive months.	9 months
Secondary	Proportion of participants with remission of low back pain as assessed by VAS at 12 months	Remission is defined as VAS score of 30mm or less for 6 consecutive months.	12 months
Secondary	Change in sleep quality as assessed by Medical Outcomes Study Sleep Scale (MOS-SS) at 3 months	The mean change in MOS-SS index from baseline.	3 months
Secondary	Change in sleep quality as assessed by MOS-SS at 6 months	The mean change in MOS-SS index from baseline.	6 months
Secondary	Change in sleep quality as assessed by MOS-SS at 12 months	The mean change in MOS-SS index from baseline.	12 months